Flood Watch
from FRI 11:00 AM MST until SAT 11:00 PM MST, Yavapai County Mountains, Little Colorado River Valley in Coconino County, Little Colorado River Valley in Navajo County, Little Colorado River Valley in Apache County, Eastern Mogollon Rim, White Mountains, Northern Gila County, Yavapai County Valleys and Basins, Oak Creek and Sycamore Canyons, Western Pima County including Ajo/Organ Pipe Cactus National Monument, Tohono O'odham Nation including Sells, Upper Santa Cruz River and Altar Valleys including Nogales, Tucson Metro Area including Tucson/Green Valley/Marana/Vail, South Central Pinal County including Eloy/Picacho Peak State Park, Southeast Pinal County including Kearny/Mammoth/Oracle, Upper San Pedro River Valley including Sierra Vista/Benson, Eastern Cochise County below 5000 ft including Douglas/Wilcox, Upper Gila River and Aravaipa Valleys including Clifton/Safford, White Mountains of Graham and Greenlee Counties including Hannagan Meadow, Galiuro and Pinaleno Mountains including Mount Graham, Chiricahua Mountains including Chiricahua National Monument, Dragoon/Mule/Huachuca and Santa Rita Mountains including Bisbee/Canelo Hills/Madera Canyon, Santa Catalina and Rincon Mountains including Mount Lemmon/Summerhaven, Baboquivari Mountains including Kitt Peak, Kofa, Central La Paz, Aguila Valley, Southeast Yuma County, Gila River Valley, Northwest Valley, Tonopah Desert, Gila Bend, Buckeye/Avondale, Cave Creek/New River, Deer Valley, Central Phoenix, North Phoenix/Glendale, New River Mesa, Scottsdale/Paradise Valley, Rio Verde/Salt River, East Valley, Fountain Hills/East Mesa, South Mountain/Ahwatukee, Southeast Valley/Queen Creek, Superior, Northwest Pinal County, West Pinal County, Apache Junction/Gold Canyon, Tonto Basin, Mazatzal Mountains, Pinal/Superstition Mountains, Sonoran Desert Natl Monument, San Carlos, Dripping Springs, Globe/Miami, Southeast Gila County

FDA finds Merck COVID-19 pill effective, seeks outside experts on safety

Federal health regulators say an experimental COVID-19 pill from Merck is effective against the virus, but they will seek input from outside experts on risks of birth defects and other potential problems in pregnant women.

The Food and Drug Administration posted its analysis of the pill ahead of a public meeting next week where academic and other experts will weigh in on its safety and effectiveness. The agency isn’t required to follow the group’s advice.

RELATED: Merck seeks FDA authorization of antiviral COVID-19 pill

The FDA scientists said their review identified several potential risks, including possible toxicity and birth defects. Regulators also noted Merck collected far less safety data overall on its drug than was gathered for other COVID-19 therapies.

All COVID-19 drugs currently authorized by the FDA require an injection or IV, which limits their use. If authorized, Merck’s drug would be the first that patients could take at home to ease symptoms and speed recovery. It is already authorized for emergency use in the U.K.

Molnupiravir Photo Illustrations

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on Nov. 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

With cases rising again across most of the U.S., regulators are expected to greenlight Merck’s drug as an important new weapon to help ease the strain on hospitals. But the FDA review is key to determining who will be eligible and how widely it might be prescribed.

FDA will ask its independent advisers whether the drug's benefits outweigh its risks and if its use should be restricted for pregnant women.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.